Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jan 14;7(1):e2042.
doi: 10.1038/cddis.2015.415.

Genetic profiling of CLL: a 'TP53 addict' perspective

L Lodé  1 , F Cymbalista  2   3   4 , T Soussi  5   6   7
Affiliations
Comment

Genetic profiling of CLL: a 'TP53 addict' perspective

L Lodé et al. Cell Death Dis. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The TP53 pathway in CLL. The level of TP53 protein is downregulated via binding of proteins, such as, MDM2 that promote TP53 degradation via the ubiquitin/proteasome pathway. As MDM2 is upregulated by TP53, this leads to a regulation loop, which maintains a very low level of TP53 protein in normal cells. This function also requires MDMX, which binds both MDM2 and TP53. Disruption of this equilibrium leading to TP53 accumulation is the main outcome of the upstream pathways to promote a TP53 biological response. In CLL, two pathways associated with DNA damage (double-strand breaks or telomere uncapping) are clearly impaired. Genes depicted in red are impaired in CLL. Whether or not trisomy 12 can alter the TP53 pathway by increasing mdm2 activity is controversial. The links between BIRC3 and the TP53 pathway remain elusive
See this image and copyright information in PMC

Comment on

  • Non-coding recurrent mutations in chronic lymphocytic leukaemia.
    Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Puente XS, et al. Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22. Nature. 2015. PMID: 26200345
  • Mutations driving CLL and their evolution in progression and relapse.
    Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Landau DA, et al. Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14. Nature. 2015. PMID: 26466571 Free PMC article.

References

    1. Puente XS et al. Nature 2015; 526: 519–524. - PubMed
    1. Landau DA et al. Nature 2015; 526: 525–530. - PMC - PubMed
    1. Leroy B et al. Hum Mutat 2014; 35: 672–688. - PubMed
    1. Calvete O et al. Nat Commun 2015; 6: 8383. - PMC - PubMed
    1. Golomb L et al. FEBS Lett 2014; 588: 2571–2579. - PubMed

MeSH terms